IGC Pharma (IGC) announced the expansion of its ongoing Phase 2 CALMA clinical trial with the addition of Butler Hospital’s Memory and Aging Program, a research center affiliated with the Warren ...

IGC Pharma Revenue Declines 51% YoY Due To Completion Of Its Legacy Project In India, Highlights Important Milestones In Alzheimer's Research Nina Zdinjak Hedge Fund Settles At $2.25M With SEC For ...

Shares of IGC Pharma, Inc. (NYSEMKT:IGC – Get Free Report) were down 7.4% on Thursday .The stock traded as low as $0.32 and last traded at $0.30. Approximately 214,616 shares changed hands ...

POTOMAC, MD / ACCESS Newswire / March 26, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced additional positive interim results from its ongoing Phase 2 ...

POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial ...

Zeit Aktuelle Nachrichten 08.04. IGC Pharma, Inc.: IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program POTOMAC, MARYLAND ...

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational ...

IGC Pharma's CALMA Phase 2 trial is being conducted in the United States, and Canada, with a goal of enrolling 146 participants. The study aims to evaluate IGC-AD1's potential in reducing ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial ...